Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.


Journal

Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225

Informations de publication

Date de publication:
05 2020
Historique:
received: 28 06 2019
revised: 28 09 2019
accepted: 15 10 2019
pubmed: 25 11 2019
medline: 6 7 2021
entrez: 25 11 2019
Statut: ppublish

Résumé

American Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controversial topic for some AI/AN. We performed a multisite retrospective chart review funded by the Minnesota Precision Medicine Grand Challenge as a demonstration project to examine lung cancer health disparities in AI/AN. We sought to measure epidemiology of lung cancer among AI receiving diagnosis or treatment in Minnesota cancer referral centers as well as rate of EGFR testing. The primary outcome was the rate of EGFR mutational analysis testing among cases and controls with nonsquamous, non-small-cell lung cancer. We secured collaborations with 5 health care systems covering a diverse geographic and demographic population. We identified 200 cases and 164 matched controls from these sites. Controls were matched on histology, smoking status, sex, and age. In both groups, about one third of subjects with adenocarcinoma received genetic mutation testing. There was no significant difference in mutation testing in AI compared to non-AI controls at large health care systems in Minnesota. These data indicate that other factors are likely contributing to the higher mortality in this group.

Sections du résumé

BACKGROUND
American Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controversial topic for some AI/AN.
PATIENTS AND METHODS
We performed a multisite retrospective chart review funded by the Minnesota Precision Medicine Grand Challenge as a demonstration project to examine lung cancer health disparities in AI/AN. We sought to measure epidemiology of lung cancer among AI receiving diagnosis or treatment in Minnesota cancer referral centers as well as rate of EGFR testing. The primary outcome was the rate of EGFR mutational analysis testing among cases and controls with nonsquamous, non-small-cell lung cancer. We secured collaborations with 5 health care systems covering a diverse geographic and demographic population.
RESULTS
We identified 200 cases and 164 matched controls from these sites. Controls were matched on histology, smoking status, sex, and age. In both groups, about one third of subjects with adenocarcinoma received genetic mutation testing.
CONCLUSION
There was no significant difference in mutation testing in AI compared to non-AI controls at large health care systems in Minnesota. These data indicate that other factors are likely contributing to the higher mortality in this group.

Identifiants

pubmed: 31759888
pii: S1525-7304(19)30286-4
doi: 10.1016/j.cllc.2019.10.012
pmc: PMC7769592
mid: NIHMS1641139
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e164-e168

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

J Am Coll Radiol. 2017 Nov;14(11):1388-1395
pubmed: 29101972
J Environ Public Health. 2014;2014:321604
pubmed: 24669226
Am J Prev Med. 2018 Apr;54(4):568-575
pubmed: 29429606
Sci Rep. 2017 Jan 04;7:39721
pubmed: 28051122
Cancer. 2017 Dec 15;123 Suppl 24:5079-5099
pubmed: 29205305
Chest. 2017 Sep;152(3):587-597
pubmed: 28450031
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Cancer. 2010 Oct 15;116(20):4810-6
pubmed: 20597131
Am J Public Health. 2016 Jul;106(7):1188-95
pubmed: 27077360
Cancer Control. 2016 Oct;23(4):338-346
pubmed: 27842323
J Natl Med Assoc. 2011 Aug;103(8):711-8
pubmed: 22046848
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pharmacogenet Genomics. 2017 May;27(5):169-178
pubmed: 28181923
J Oncol Pract. 2019 Apr;15(4):e289-e299
pubmed: 30830833
Onco Targets Ther. 2017 Aug 29;10:4295-4303
pubmed: 28919778
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
J Health Care Poor Underserved. 2019;30(2):431-441
pubmed: 31130528
Lung Cancer. 2018 Oct;124:53-64
pubmed: 30268480
Risk Anal. 2012 Jul;32 Suppl 1:S69-84
pubmed: 22882894

Auteurs

Abbie Begnaud (A)

Department of Medicine, University of Minnesota, Minneapolis, MN.

Ping Yang (P)

Departments of Internal Medicine and Medical Genetics, Mayo Clinic, Scottsdale, AZ.

Camille Robichaux (C)

Department of Medicine, University of Minnesota, Minneapolis, MN. Electronic address: robic020@umn.edu.

Nathan Rubin (N)

Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.

Robert Kratzke (R)

Department of Medicine, University of Minnesota, Minneapolis, MN.

Anne Melzer (A)

Section of Pulmonary and Critical Care, Minneapolis VA Healthcare System, Minneapolis, MN.

Constantin Aliferis (C)

Department of Medicine, University of Minnesota, Minneapolis, MN.

Pamala Jacobson (P)

Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH